Increasing prevalence of genetic diseases such as Down syndrome, Edward syndrome and Patau syndrome in new born and prenatal is the high impact rendering driver for the growth of prenatal and new-born genetic testing market. Increasing demand for prenatal and new-born genetic testing for identifying genetic abnormalities and determining the sex of fetus before 8 to 11 months gestation are the driving factors for the growth of this market. Some other drivers for prenatal and new-born genetic testing market include increasing R&D activities related to genomics and proteomics, extensive presence of public and private public organizations such as the National Human Genome Research Institute (NHGRI) and Genomic Health Inc. and advancement in technology. Increasing approaches for novel diagnostic techniques and tools and emerging genome profiling technologies such as TaqMan PCR are expected to grow this market at the rapid pace.
On the basis of technology, prenatal and new-born genetic testing market is segmented into diagnostics methods and screening techniques. Diagnostics methods are classified into PCR (polymerase chain reaction), aCGH (array-comparative genetic hybridization) and (FISH (fluorescence in-situ hybridization). However, screening techniques are segmented into non-invasive prenatal tests includes Verifi, Harmony, MaterniT21 Plus, Panorama, PrenaTest, NIFTY, and Bambni Test) and MMS (maternal serum screening). Polymerase chain reaction is a technique in which a single piece or a few copies of DNA are used to amplify millions of copies of particular sequence of DNA. It is the most common and indispensible technique used in biological and medical research laboratories for wide range of applications such as DNA-based phylogeny, genetic fingerprints identification, diagnosis of hereditary diseases and functional analysis of genes.
The global prenatal and newborn genetic testing is segmented into four major regions such as Europe, North America, Asia- Pacific and RoW. The North American market is considered as most dominant market due to favorable government policies towards proper diagnosis and screening of genetic abnormalities and the presence of advanced technologies such as multiplex PCR technologies and real time PCR equipment. Asia-Pacific market is expected to show lucrative growth during the forecast period owing to the development of various plans and policies of government, improvements in healthcare services, rising awareness of genetic disease diagnosis and rising economic development. Key players in this market include Bio-Rad Laboratories Inc., Agilent Technologies Inc., Illumina, Inc. and Natera Inc.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."